107
Views
5
CrossRef citations to date
0
Altmetric
Articles

Imatinib Mesylate (Gleevec™) is a Useful Agent in the Salvage Treatment of Adults with Relapsed/refractory Philadelphia Positive Acute Leukemias

, , , , &
Pages 139-143 | Published online: 04 Sep 2013

References

  • Westbrook, C.A., Hooberman, AL., Spino, C., Dodge, R.K., Larson, R.A., Davey, F., Wurster-Hill, D.H, Sobol, R.E., Schiffer, C. and Bloomfield, C.D. (1992) "Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762)", Blood 80, 2983–2990.
  • Paietta, E., Racevskis, J., Bennett, J.M., Neuberg, D., Cassileth, P.A., Rowe, J.M. and Wiernik, P.H. (1998) "Biologic heterogeneity in Philadelphia chromosome-posi-tive acute leukemia with myeloid morphology: the Eastern Cooperative Oncology Group experience", Leukemia 12, 1881–1885.
  • Garcia-Manero, G. and Kantarjian, H.M. (2000) "The hyper-CVAD regimen in adult acute lymphocytic leukemia", Hematol. Oncol. Clin. N. Am. 14, 1381–1396, x—xi.
  • Barrett, A.J., Horowitz, M.M., Ash, R.C., Atkinson, K., Gale, R.P., Goldman, J.M., Henslee-Downey, P.J, Herzig, R.H., Speck, B., Zwaan, F.E., et al. (1992) "Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia", Blood 79, 3067–3070.
  • Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R. and Talpaz, M. (2001) "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympho-blastic leukemia with the Philadelphia chromosome", N. Engl. J. Med. 344, 1038–1042.
  • Ottmann, O.G., Druker, B.J., Sawyers, C.L., Goldman, J.M., Reiffers, J., Silver, R.T., Tura, S., Fischer, T., Deininger, M.W., Schiffer, C.A., Baccarani, M., Gratwohl, A., Hochhaus, A., Hoelzer, D., Fernandes-Reese, S., Gathmann, I., Capdeville, R. and O'Brien, S.G. (2002) "A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromo-some-positive acute lymphoid leukemias", Blood 100, 1965–1971.
  • Branford, S., Hughes, T.P. and Rudzki, Z. (1999) "Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics", Br. J. Haematol. 107, 587–599.
  • Catovsky, D., Matutes, E., Buccheri, V, Shetty, V, Hanslip, J., Yoshida, N. and Morilla, R. (1991) "A classification of acute leukaemia for the 1990s", Ann. Hematol. 62, 16–21.
  • Collins, R.H., Jr, Shpilberg, O., Drobyski, W.R., Porter, D.L., Giralt, S., Champlin, R., Goodman, S.A., Wolff, S.N., Hu, W., Verfaillie, C., List, A., Dalton, W., Ognoskie, N., Chetrit, A., Antin, J.H. and Nemunaitis, J. (1997) "Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation", J. Clin. Oncol. 15, 433–444.
  • Nollet, F., Billiet, J., Selleslag, D. and Criel, A. (2001) "Standardisation of multiplex fluorescent short tandem repeat analysis for chimerism testing", Bone Marrow Transplant. 28, 511–518.
  • Daly, A.S., Messner, H.A., Hasegawa, W.S., Kiss, T.L. and Lipton, J.H. (2002) "Outcome of allogeneic bone marrow transplant in recipients of prior high-dose chemotherapy: comparison with case-matched controls", Biol. Blood Marrow Transplant. 8, 76.
  • Chambon-Pautas, C., Yakouben, K., Cony-Makhoul, P., Maillard, N., Contentin, N., Guilhot, E, Cordonnier, C. and Berthaud, M.K. (2001) "Stem cell transplantation (SCT) after successful therapy with Glivec (5TI571) for poo prognosis PM-positive (Phl+ ) malignancies", Blood 98, 328a.
  • Fleming, D.R., Henslee-Downey, P.J., Romond, E.H., Harder, E.J., Marciniak, E., Murm, R.K., Messino, M.J., Macdonald, J.S., Bishop, M., Rayens, M.K., Thompson, J.S. and Foon, K.A. (1996) "Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a compara-tive matched cohort study", Bone Marrow Transplant. 17, 917–922.
  • Scheuring, U.J., Pfeifer, H., Brueck, P., Wassmann, B., Atta, J., Gschaidmeier, H., Petershofen, E., Hoelzer, D.F. and Ottmann, O.G. (2001) "Prognostic relevance of Minimal residual disease (MRD) analysis in BCR-ABL positive acute Lymphoblastic leukemia (ALL) patients during Gleevec (5TI571) therapy", Blood 98, 762a–763a.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.